Surface engineering through low temperature deposition of wear resistant layers by reactive magnetron sputter ion plating

The aim of this investigation was the deposition of hard» wear resistant titanium nitride (TiN) thin films, produced from a reactive magnetron sputter ion plating device, at high deposition rates and low substrate temperatures. An allied objective vas the understanding and development of experimental methods which would permit the deposition of titanium nitride-type layers on plastic. The early part of the work deals with the formation of TiN layers on high speed steel, at 500°C deposition temperature Modifications in equipment design and deposition procedures aided the formation of adherent TiN layers. The routine deposition of stoichiometric titanium nitride vas facilitated by a control feedback network The use of graded interfaces between the film and the substrate improved adhesion. Total gas pressure and the level of substrate bias affect film hardness and wear resistance. The next stage of the development process vas the deposition of TiN at approximately 250°C substrate temperature. The main source of substrate heating, in the case of an indirectly cooled magnetron, was identified as the heat liberated from the target. The use of a directly cooled magnetron configuration resulted in lover substrate temperatures. With this device, TiN films vere formed on high speed steel at high deposition rates and with good adhesion. The increased ion current to the substrate is, tentatively, attributed to an extended plasma region associated with the directly cooled configuration Metastable T^N phases are formed from the combination of high deposition rates, low substrate temperatures (250°C) and increased ion bombardment to the substrate. These TiN films, however, are softer and less wear resistant than those produced at 500°C. The final part of the investigation centred around the deposition of TiN type layers onto plastic T1 -T1 N and AI-T1 -T1N layered structures were deposited onto polycarbonate plastic at 100°C. An experimental design approach was employed to develop adhering coatings. A slight partial pressure of oxygen during the initial Ti deposition improves film adhesion. The use of the aluminium interface improves film reflectivity, cosmetic appearance and adhesion. This aluminium interface makes the multilayer structure more susceptible to physical and chemical attack. The wear resistance of the coated plastic is 2 to 4 times greater than the base plastic material

Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response

AbstractInfection with the bacterium Clostridium difficile causes symptoms ranging from mild to severe diarrhoea with life-threatening complications and remains a significant burden to healthcare systems throughout the developed world. Two potent cytotoxins, TcdA and TcdB are the prime mediators of the syndrome and rapid neutralisation of these would afford significant benefits in disease management. In the present study, a broad range of non-toxic, recombinant fragments derived from TcdA and TcdB were designed for soluble expression in E. coli and assessed for their capacity to generate a potent toxin-neutralising immune response as assessed by cell-based assays. Significant differences between the efficacies of isolated TcdA and TcdB regions with respect to inducing a neutralising immune response were observed. While the C-terminal repeat regions played the principal role in generating neutralising antibodies to TcdA, in the case of TcdB, the central region domains dominated the neutralising immune response. For both TcdA and TcdB, fragments which comprised domains from both the central and C-terminal repeat region of the toxins were found to induce the most potent neutralising immune responses. Generated antibodies neutralised toxins produced by a range of C. difficile isolates including ribotype 027 and 078 strains. Passive immunisation of hamsters with a combination of antibodies to TcdA and TcdB fragments afforded complete protection from severe CDI induced by a challenge of bacterial spores. The results of the study are discussed with respect to the development of a cost effective immunotherapeutic approach for the management of C. difficile infection

Wear Testing of the HERMeS Thruster

The Hall-Effect Rocket with Magnetic Shielding (HERMeS) thruster is being developed and tested at NASA GRC and NASA JPL through support of the Space Technology Mission Directorate (STMD) as primary propulsion for the Asteroid Rendezvous and Redirect Mission (ARRM). This thruster is advancing the state of the art of hall-effect thrusters (HETs) and is intended to serve as a precursor to higher power systems for human interplanetary exploration. The HERMeS Thruster Demonstration Unit One (TDU-1) has entered a 2000-hour wear test campaign at NASA GRC and has completed the first three of four test segments totaling 728 hours of operation. This is the first test of a NASA-designed magnetically shielded thruster to extend beyond 300 hours of continuous operation

Effect of a Perioperative, Cardiac Output-Guided Hemodynamic Therapy Algorithm on Outcomes Following Major Gastrointestinal Surgery A Randomized Clinical Trial and Systematic Review

Importance: small trials suggest that postoperative outcomes may be improved by the use of cardiac output monitoring to guide administration of intravenous fluid and inotropic drugs as part of a hemodynamic therapy algorithm.Objective: to evaluate the clinical effectiveness of a perioperative, cardiac output–guided hemodynamic therapy algorithm.Design, setting, and participants: OPTIMISE was a pragmatic, multicenter, randomized, observer-blinded trial of 734 high-risk patients aged 50 years or older undergoing major gastrointestinal surgery at 17 acute care hospitals in the United Kingdom. An updated systematic review and meta-analysis were also conducted including randomized trials published from 1966 to February 2014.Interventions: patients were randomly assigned to a cardiac output–guided hemodynamic therapy algorithm for intravenous fluid and inotrope (dopexamine) infusion during and 6 hours following surgery (n=368) or to usual care (n=366).Main outcomes and measures: the primary outcome was a composite of predefined 30-day moderate or major complications and mortality. Secondary outcomes were morbidity on day 7; infection, critical care–free days, and all-cause mortality at 30 days; all-cause mortality at 180 days; and length of hospital stay.Results: baseline patient characteristics, clinical care, and volumes of intravenous fluid were similar between groups. Care was nonadherent to the allocated treatment for less than 10% of patients in each group. The primary outcome occurred in 36.6% of intervention and 43.4% of usual care participants (relative risk [RR], 0.84 [95% CI, 0.71-1.01]; absolute risk reduction, 6.8% [95% CI, ?0.3% to 13.9%]; P?=?.07). There was no significant difference between groups for any secondary outcomes. Five intervention patients (1.4%) experienced cardiovascular serious adverse events within 24 hours compared with none in the usual care group. Findings of the meta-analysis of 38 trials, including data from this study, suggest that the intervention is associated with fewer complications (intervention, 488/1548 [31.5%] vs control, 614/1476 [41.6%]; RR, 0.77 [95% CI, 0.71-0.83]) and a nonsignificant reduction in hospital, 28-day, or 30-day mortality (intervention, 159/3215 deaths [4.9%] vs control, 206/3160 deaths [6.5%]; RR, 0.82 [95% CI, 0.67-1.01]) and mortality at longest follow-up (intervention, 267/3215 deaths [8.3%] vs control, 327/3160 deaths [10.3%]; RR, 0.86 [95% CI, 0.74-1.00]).Conclusions and relevance: in a randomized trial of high-risk patients undergoing major gastrointestinal surgery, use of a cardiac output–guided hemodynamic therapy algorithm compared with usual care did not reduce a composite outcome of complications and 30-day mortality. However, inclusion of these data in an updated meta-analysis indicates that the intervention was associated with a reduction in complication rate

Recommendations for Addressing Priority Io Science in the Next Decade

Io is a priority destination for solar system exploration. The scope and importance of science questions at Io necessitates a broad portfolio of research and analysis, telescopic observations, and planetary missions - including a dedicated New Frontiers class Io mission

The Science Case for Io Exploration

Io is a priority destination for solar system exploration, as it is the best natural laboratory to study the intertwined processes of tidal heating, extreme volcanism, and atmosphere-magnetosphere interactions. Io exploration is relevant to understanding terrestrial worlds (including the early Earth), ocean worlds, and exoplanets across the cosmos

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19

Comparing the AUSCAN osteoarthritis hand index, Michigan hand outcome questionnaire, and sequential occupational dexterity assessment for patients with rheumatoid arthiritis

920 YONGE ST, SUITE 115, TORONTO, CANADA, ONTARIO, M4W 3C